These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 9008491)
1. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group. Neurology; 1997 Jan; 48(1):38-46. PubMed ID: 9008491 [TBL] [Abstract][Full Text] [Related]
2. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. Tawil R; McDermott MP; Pandya S; King W; Kissel J; Mendell JR; Griggs RC Neurology; 1997 Jan; 48(1):46-9. PubMed ID: 9008492 [TBL] [Abstract][Full Text] [Related]
3. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Tawil R; McDermott MP; Mendell JR; Kissel J; Griggs RC Neurology; 1994 Mar; 44(3 Pt 1):442-6. PubMed ID: 8145913 [TBL] [Abstract][Full Text] [Related]
4. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group. Personius KE; Pandya S; King WM; Tawil R; McDermott MP Phys Ther; 1994 Mar; 74(3):253-63. PubMed ID: 8115459 [TBL] [Abstract][Full Text] [Related]
5. A longitudinal study of disease progression in facioscapulohumeral muscular dystrophy (FSHD). Varma A; Todinca MS; Eichinger K; Heininger S; Dilek N; Martens W; Tawil R; Statland J; Kissel JT; McDermott MP; Heatwole C Muscle Nerve; 2024 Mar; 69(3):362-367. PubMed ID: 38189531 [TBL] [Abstract][Full Text] [Related]
6. Monozygotic twins with facioscapulohumeral dystrophy (FSHD): implications for genotype/phenotype correlation. FSH-DY Group. Griggs RC; Tawil R; McDermott M; Forrester J; Figlewicz D; Weiffenbach B Muscle Nerve Suppl; 1995; 2():S50-5. PubMed ID: 7739626 [TBL] [Abstract][Full Text] [Related]
7. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Kissel JT; McDermott MP; Natarajan R; Mendell JR; Pandya S; King WM; Griggs RC; Tawil R Neurology; 1998 May; 50(5):1402-6. PubMed ID: 9595995 [TBL] [Abstract][Full Text] [Related]
8. [Facioscapulohumeral muscular dystrophy (FSHD)]. Funakoshi M; Goto K; Kim BY; Arahata K Nihon Rinsho; 1997 Dec; 55(12):3181-5. PubMed ID: 9436432 [TBL] [Abstract][Full Text] [Related]
10. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD). Goselink RJ; Schreuder TH; Mul K; Voermans NC; Pelsma M; de Groot IJ; van Alfen N; Franck B; Theelen T; Lemmers RJ; Mah JK; van der Maarel SM; van Engelen BG; Erasmus CE BMC Neurol; 2016 Aug; 16():138. PubMed ID: 27530735 [TBL] [Abstract][Full Text] [Related]
11. The influence of handedness on the distribution of muscular weakness of the arm in facioscapulohumeral muscular dystrophy. Brouwer OF; Padberg GW; van der Ploeg RJ; Ruys CJ; Brand R Brain; 1992 Oct; 115 ( Pt 5)():1587-98. PubMed ID: 1422805 [TBL] [Abstract][Full Text] [Related]
12. Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. Statland JM; McDermott MP; Heatwole C; Martens WB; Pandya S; van der Kooi EL; Kissel JT; Wagner KR; Tawil R Neuromuscul Disord; 2013 Apr; 23(4):306-12. PubMed ID: 23406877 [TBL] [Abstract][Full Text] [Related]
13. The strength and functional performance in patients with facioscapulohumeral muscular dystrophy. Lue YJ; Chen SS Kaohsiung J Med Sci; 2000 May; 16(5):248-54. PubMed ID: 10969520 [TBL] [Abstract][Full Text] [Related]
14. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. LoRusso S; Johnson NE; McDermott MP; Eichinger K; Butterfield RJ; Carraro E; Higgs K; Lewis L; Mul K; Sacconi S; Sansone VA; Shieh P; van Engelen B; Wagner K; Wang L; Statland JM; Tawil R; BMC Neurol; 2019 Sep; 19(1):224. PubMed ID: 31506080 [TBL] [Abstract][Full Text] [Related]
15. Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1-year follow-up study. Mul K; Heatwole C; Eichinger K; Dilek N; Martens WB; Van Engelen BGM; Tawil R; Statland JM Muscle Nerve; 2018 Aug; 58(2):213-218. PubMed ID: 29543984 [TBL] [Abstract][Full Text] [Related]
16. Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Kilmer DD; Abresch RT; McCrory MA; Carter GT; Fowler WM; Johnson ER; McDonald CM Am J Phys Med Rehabil; 1995; 74(5 Suppl):S131-9. PubMed ID: 7576420 [TBL] [Abstract][Full Text] [Related]
17. Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging. Monforte M; Laschena F; Ottaviani P; Bagnato MR; Pichiecchio A; Tasca G; Ricci E J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1258-1265. PubMed ID: 31668022 [TBL] [Abstract][Full Text] [Related]
19. Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome. Vincenten SCC; Mul K; van As D; Jansen JJ; Heskamp L; Heerschap A; van Engelen BGM; Voermans NC J Cachexia Sarcopenia Muscle; 2023 Aug; 14(4):1695-1706. PubMed ID: 37218549 [TBL] [Abstract][Full Text] [Related]